Benign by design: Benign by Design

Research output: Contributions to collected editions/worksChapterpeer-review

Standard

Benign by design : Benign by Design. / Kümmerer, Klaus.

Green and Sustainable Medicinal Chemistry: Methods, Tools and Strategies for the 21st Century Pharmaceutical Industry. ed. / Louise Summerton; Helen F. Sneddon; Leonie C. Jones; James H. Clark. Cambridge : Royal Society of Chemistry, 2016. p. 73-81 (RSC Green Chemistry; Vol. 2016-January, No. 46).

Research output: Contributions to collected editions/worksChapterpeer-review

Harvard

Kümmerer, K 2016, Benign by design: Benign by Design. in L Summerton, HF Sneddon, LC Jones & JH Clark (eds), Green and Sustainable Medicinal Chemistry: Methods, Tools and Strategies for the 21st Century Pharmaceutical Industry. RSC Green Chemistry, no. 46, vol. 2016-January, Royal Society of Chemistry, Cambridge, pp. 73-81. https://doi.org/10.1039/9781782625940-00073

APA

Kümmerer, K. (2016). Benign by design: Benign by Design. In L. Summerton, H. F. Sneddon, L. C. Jones, & J. H. Clark (Eds.), Green and Sustainable Medicinal Chemistry: Methods, Tools and Strategies for the 21st Century Pharmaceutical Industry (pp. 73-81). (RSC Green Chemistry; Vol. 2016-January, No. 46). Royal Society of Chemistry. https://doi.org/10.1039/9781782625940-00073

Vancouver

Kümmerer K. Benign by design: Benign by Design. In Summerton L, Sneddon HF, Jones LC, Clark JH, editors, Green and Sustainable Medicinal Chemistry: Methods, Tools and Strategies for the 21st Century Pharmaceutical Industry. Cambridge: Royal Society of Chemistry. 2016. p. 73-81. (RSC Green Chemistry; 46). doi: 10.1039/9781782625940-00073

Bibtex

@inbook{dff3f927731247a09fad4f7fbecb89ef,
title = "Benign by design: Benign by Design",
abstract = "Active pharmaceutical ingredients (APIs) and adjuvants of medications are often excreted unchanged (i.e. as active compounds) or as metabolites. It has been found that their removal during sewage treatment-if in place-has severe limitations and is often not sustainable. APIs may degrade incompletely in the environment thus resulting in numerous transformation products (TPs). Both parent compounds (PCs) and TPs are present in the environment. As so-called 'micro-pollutants' they may constitute a risk to the environment and the consumer. They represent a big obstacle for the sustainable management of water resources worldwide. Furthermore, testing and risk assessment will neither be possible nor affordable for all compounds, due to the sheer number of APIs but also the number of transformation products to be tested and identified. With respect to increasing population and increasing standards of living, the problem is likely to be more severe in the future. Therefore it is necessary to find solutions that prevent the input of pharmaceuticals into the environment from the very beginning of the design process. Developing new API molecules and adjuvants that are rapidly and fully mineralized after they leave the body is such an approach. This 'Benign by Design'-paradigm will not only contribute to a more sustainable pharmacy, it encourages the development of new products by encouraging innovation which will potentially widen its impact.",
keywords = "Chemistry, green chemistry",
author = "Klaus K{\"u}mmerer",
year = "2016",
month = mar,
day = "14",
doi = "10.1039/9781782625940-00073",
language = "English",
isbn = "978-1-78262-467-7",
series = "RSC Green Chemistry",
publisher = "Royal Society of Chemistry",
number = "46",
pages = "73--81",
editor = "Louise Summerton and Sneddon, {Helen F.} and Jones, {Leonie C.} and Clark, {James H.}",
booktitle = "Green and Sustainable Medicinal Chemistry",
address = "United Kingdom",

}

RIS

TY - CHAP

T1 - Benign by design

T2 - Benign by Design

AU - Kümmerer, Klaus

PY - 2016/3/14

Y1 - 2016/3/14

N2 - Active pharmaceutical ingredients (APIs) and adjuvants of medications are often excreted unchanged (i.e. as active compounds) or as metabolites. It has been found that their removal during sewage treatment-if in place-has severe limitations and is often not sustainable. APIs may degrade incompletely in the environment thus resulting in numerous transformation products (TPs). Both parent compounds (PCs) and TPs are present in the environment. As so-called 'micro-pollutants' they may constitute a risk to the environment and the consumer. They represent a big obstacle for the sustainable management of water resources worldwide. Furthermore, testing and risk assessment will neither be possible nor affordable for all compounds, due to the sheer number of APIs but also the number of transformation products to be tested and identified. With respect to increasing population and increasing standards of living, the problem is likely to be more severe in the future. Therefore it is necessary to find solutions that prevent the input of pharmaceuticals into the environment from the very beginning of the design process. Developing new API molecules and adjuvants that are rapidly and fully mineralized after they leave the body is such an approach. This 'Benign by Design'-paradigm will not only contribute to a more sustainable pharmacy, it encourages the development of new products by encouraging innovation which will potentially widen its impact.

AB - Active pharmaceutical ingredients (APIs) and adjuvants of medications are often excreted unchanged (i.e. as active compounds) or as metabolites. It has been found that their removal during sewage treatment-if in place-has severe limitations and is often not sustainable. APIs may degrade incompletely in the environment thus resulting in numerous transformation products (TPs). Both parent compounds (PCs) and TPs are present in the environment. As so-called 'micro-pollutants' they may constitute a risk to the environment and the consumer. They represent a big obstacle for the sustainable management of water resources worldwide. Furthermore, testing and risk assessment will neither be possible nor affordable for all compounds, due to the sheer number of APIs but also the number of transformation products to be tested and identified. With respect to increasing population and increasing standards of living, the problem is likely to be more severe in the future. Therefore it is necessary to find solutions that prevent the input of pharmaceuticals into the environment from the very beginning of the design process. Developing new API molecules and adjuvants that are rapidly and fully mineralized after they leave the body is such an approach. This 'Benign by Design'-paradigm will not only contribute to a more sustainable pharmacy, it encourages the development of new products by encouraging innovation which will potentially widen its impact.

KW - Chemistry

KW - green chemistry

UR - http://www.scopus.com/inward/record.url?scp=84975079891&partnerID=8YFLogxK

U2 - 10.1039/9781782625940-00073

DO - 10.1039/9781782625940-00073

M3 - Chapter

SN - 978-1-78262-467-7

T3 - RSC Green Chemistry

SP - 73

EP - 81

BT - Green and Sustainable Medicinal Chemistry

A2 - Summerton, Louise

A2 - Sneddon, Helen F.

A2 - Jones, Leonie C.

A2 - Clark, James H.

PB - Royal Society of Chemistry

CY - Cambridge

ER -